Integra LifeSciences (NASDAQ:IART) Releases Q3 2026 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its third quarter 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 0.530-0.610 for the period, compared to the consensus EPS estimate of 0.560. The company issued revenue guidance of $410.0 million-$425.0 million, compared to the consensus revenue estimate of $417.3 million. Integra LifeSciences also updated its FY 2026 guidance to 2.400-2.500 EPS.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on IART shares. Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Truist Financial increased their target price on shares of Integra LifeSciences from $14.00 to $19.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research report on Thursday, June 18th. Wall Street Zen lowered Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, UBS Group began coverage on Integra LifeSciences in a report on Tuesday. They issued a “neutral” rating and a $19.00 price target for the company. One research analyst has rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $18.86.

Integra LifeSciences Price Performance

NASDAQ IART traded up $1.23 on Thursday, reaching $17.71. The company’s stock had a trading volume of 347,989 shares, compared to its average volume of 903,815. Integra LifeSciences has a 52 week low of $8.70 and a 52 week high of $20.49. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75. The firm has a market cap of $1.38 billion, a PE ratio of -2.75, a price-to-earnings-growth ratio of 1.37 and a beta of 1.22. The business has a 50-day moving average price of $17.63 and a 200 day moving average price of $13.42.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.08. The firm had revenue of $418.76 million during the quarter, compared to analysts’ expectations of $417.54 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Sell-side analysts expect that Integra LifeSciences will post 2.45 EPS for the current year.

Integra LifeSciences News Roundup

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Integra reported second-quarter earnings of $0.56 per share, above the $0.48 analyst consensus and up from $0.45 a year earlier. Revenue of $418.8 million was essentially in line with estimates. Integra LifeSciences Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Wells Fargo raised its price target for IART from $15 to $18. Although the firm maintained an “equal weight” rating, the higher target reflects improved valuation support and leaves modest additional upside from recent trading levels. Wells Fargo Raises Integra LifeSciences Price Target
• Positive Sentiment: Technical screens identified Integra as a potential breakout stock trading near its 52-week high, suggesting continued momentum could attract additional buyers. Stocks Showing Breakout Potential
• Neutral Sentiment: Management guided to third-quarter EPS of $0.53-$0.61 and revenue of $410 million-$425 million, broadly consistent with Wall Street expectations. Full-year EPS guidance of $2.40-$2.50 also brackets the $2.45 consensus, limiting the potential for a major estimate-driven re-rating. Integra LifeSciences Second-Quarter Results
• Neutral Sentiment: UBS began coverage of Integra, adding fresh institutional research coverage; the available report does not specify its rating or price target. UBS Begins Coverage on Integra LifeSciences

Institutional Investors Weigh In On Integra LifeSciences

Several institutional investors and hedge funds have recently made changes to their positions in the company. Global Retirement Partners LLC acquired a new stake in shares of Integra LifeSciences during the 4th quarter worth about $25,000. Osaic Holdings Inc. boosted its position in Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after buying an additional 1,104 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Integra LifeSciences by 595.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after buying an additional 6,814 shares during the last quarter. Virtu Financial LLC bought a new stake in Integra LifeSciences during the fourth quarter worth about $124,000. Finally, Amundi increased its holdings in shares of Integra LifeSciences by 17,193.8% during the second quarter. Amundi now owns 11,068 shares of the life sciences company’s stock worth $150,000 after buying an additional 11,004 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.